Detalhe da pesquisa
1.
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Cancer Immunol Immunother
; 73(7): 116, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713408
2.
Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
J Neurooncol
; 158(3): 471-480, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665462
3.
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Lancet Oncol
; 22(12): 1692-1704, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774225
4.
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
N Engl J Med
; 379(8): 722-730, 2018 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30134131
5.
First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis.
Future Oncol
; 17(6): 689-699, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33084375
6.
Management of Melanoma during Pregnancy: A Case Series of 11 Women Treated at NYU Langone Health.
Oncology
; 98(12): 847-852, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894847
7.
Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer.
Facial Plast Surg
; 36(2): 200-210, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32413929
8.
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Cancer
; 125(7): 1113-1123, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30690710
9.
Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Future Oncol
; 15(4): 349-358, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30334646
10.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med
; 372(21): 2006-17, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891304
11.
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.
J Transl Med
; 16(1): 82, 2018 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29606147
12.
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
Invest New Drugs
; 36(1): 103-113, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127533
13.
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
Oncology
; 93(4): 249-258, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28746931
14.
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Oncology
; 93(3): 164-176, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28601879
15.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 17(11): 1558-1568, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622997
16.
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Invest New Drugs
; 34(4): 439-49, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27056178
17.
Metastatic Cutaneous Squamous Cell Carcinoma: The Importance of T2 Stratification and Hematologic Malignancy in Prognostication.
Dermatol Surg
; 42(8): 932-5, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27467226
18.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Lancet Oncol
; 16(8): 908-18, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26115796
19.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
N Engl J Med
; 366(8): 707-14, 2012 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22356324
20.
Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy.
J Transl Med
; 12: 342, 2014 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25491880